Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Neulasta trial results published in The Journal of Clinical Oncology
March 31st, 2005
Amgen Inc. (AMGN) announced that data from the largest randomized placebo controlled study to date for Neulasta (pegfilgrastim) has been published in The Journal of Clinical Oncology. The phase 3 study showed that administering Neulasta beginning in the first and subsequent cycles of chemotherapy reduced the incidence of febrile neutropenia (low white blood cell count with fever), a serious complication of cancer chemotherapy typically associated with infection, by more than 90%. "In this study, Neulasta administered 24 hours after chemotherapy profoundly reduced the rate of febrile neutropenia from 17% to 1%," said the study's lead...
Source: Women's Health Weekly (2005-03-31)
|
